Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.
After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.
'API prices are dragging down margins and impacting our competitive ability.'
'However, we have seen weakness in our active pharmaceutical ingredients business.'
The previous two sessions have seen benchmark indices, the BSE Sensex and Nifty presenting signs of fatigue, reaching closer to its all-time highs level. Both indices are down approximately 1 per cent from recent highs and 2 per cent away from reaching a new peak. This has led to confusion on the street about its ability to reach another milestone. The present bullish trend in the leading indices; which has displayed smart recovery since late March this year, remains intact as the market breadth continues to stay elevated.
'I cannot cope with the demand. It will take us a couple of months to ramp up production.'
Given the gestation period for regulatory clearances it is not possible to share any definite timelines.
The government has also given permission to 20 plants to produce the antiviral drug.
'This government did not have any plan for safety stocks of essential medicines.'
This import duty exemption would remain in force till October 31 this year.
Cadila, Biocon developing rapid antibody testing kits; Eris, Mylan, Gland importing. There are two kinds of testing for the novel coronavirus - the real-time polymerase chain reaction test kit that uses throat or nasal swabs and provides results in a few hours, and the other is antibody-based rapid testing kit that use blood samples and provides results in a few minutes.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
'We are going to be overwhelmed by the need for hospital beds. There are simply not enough beds in government hospitals.' 'We will need a large number of medical professionals and without the private sector's involvement, the government won't be able to expand capacity.'
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
Torrent Pharmaceuticals' Rs 3,000 crore proposal for increasing FII investment limit to 35 per cent was the biggest in terms of value
The story of Kiran Mazumdar-Shaw is one of grit, self confidence and courage. If today she is one of the most successful entrepreneurs in the world, it is because of her determination.
After registering encouraging data from oral insulin trials, Biocon is looking to partner on this with global pharma firms.
New drug discovery and contract research have taken a back seat as global drug majors have slowed down their research and development offshoring to India.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The test used now, called PCR (or polymerace chain reaction), uses a nasal or throat swab sample and identifies the virus. These tests take at least five hours to give results. The rapid test, on the other hand, uses a blood sample and gives results based on detecting the presence of certain antibodies that react to the coronavirus protein.
FIPB has deferred 18 proposals.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
This was the biggest IPO in the Indian market since Infratel's.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Savitri Jindal has retained the tag of being the richest woman in India with a networth of $5.2 billion
Investment bankers said retail investors were pulling back, while institutions were being pickier
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
HSBC maintained "overweight" rating on Indian equities, saying "fundamentals are strong".
Kiran Mazumdar-Shaw talks to Nikita Puri about her book Mythbreaker.
Asian markets were trading mixed with shares in China witnessing profit taking after sharp gains in the previous session.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' stock market queries. Ajit will offer his unbiased views on a weekly basis
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances